Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2011-06-28
2011-06-28
Peng, Bo (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S008000
Reexamination Certificate
active
07968286
ABSTRACT:
Described are of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, described are assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.
REFERENCES:
patent: 5922315 (1999-07-01), Roy
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6670188 (2003-12-01), Vogels et al.
patent: 6733993 (2004-05-01), Emini et al.
patent: 6913922 (2005-07-01), Bout et al.
patent: 2003/0044421 (2003-03-01), Emini et al.
patent: 99201545.3 (1999-05-01), None
patent: 0 978 566 (2000-02-01), None
patent: WO 96/26281 (1996-08-01), None
patent: WO 98/32842 (1998-07-01), None
patent: WO 98/50053 (1998-11-01), None
patent: WO 99/64582 (1999-12-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/60106 (2000-10-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/02607 (2001-01-01), None
patent: WO 01/21201 (2001-03-01), None
patent: WO 02/22080 (2002-03-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/053759 (2002-07-01), None
patent: WO 2004/028478 (2004-04-01), None
Anderson, et al.; A simple method for the rapid generation of recombinant adenovirus vectors; Gene Ther., Jun. 8, 2000; 7 (12); pp. 1034-1038.
Basler. et al.; Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35, Gene, 1996 pp. 249-254, vol. 170.
Bostic. et al., Quantitative Analysis of Neutralizing Immune Response to Human Parvovirus BI9 Using a Novel Reverse Transcriptase-Polymerase Chain Reaction-Based Assay, Journal of Infectious Disease, 1999, pp. 619-626, vol. 179, Chicago, IL, US.
European Search Report, EP 03 780 172, dated Dec. 6, 2007.
Flomenberg, et al.; Sequence and genetic Organization of Adenovirus Type 35 Early Region 3; Journal of Virology. Nov. 1988, pp. 4431-4437, vol. 62, No. 11.
Flomenberg, et al; Molecular Epidemiololgy of Adenovirus Type 35 Infections in Immunocompromised Hosts; The Journal of Infectious Diseases, Jun. 1987, pp. 1127-1134, vol. 155, No. 6.
Gaher Y-Segard, et al.; Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have Synergistic Effect on Neutralizing Activity; Journal of Virology. Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
Hsu, et al., Immunogenicity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenovirus Types 4, 5, and 7 Vectors in Dogs and a chimpanzee; Journal of Infectious Diseases, Oct. 1, 1992, pp. 769-775, vol. 166, No. 4.
Kang, et al.; Molecular Cloning and Physical Mapping of the DNA of Human Adenovirus Type 35, Acta Microbiologica Hungarica 1999, pp. 67-75, vol. 36, No. 1.
Kass-Eisler. et al.: Circumventing the immune response to adenovirus-mediated gene therapy; Gene Therapy, Feb. 1, 1996, pp. 154-162, vol. 2. No. 3.
Klein, et al.; Accurate estimation of transduction efficiency necessitates a multiplex real-time PCT, Gene Therapy, 2000, pp. 458-463, vol. 7.
Krasnykh, et al.; Generation of Recombinant Adenovirus Vectors with modified Fibers for Altering Viral Tropism. Journal of Virology. Oct. 1996. pp. 6839-6846, vol. 70. No. 10.
Liu, et al., Is Green Fluorescent Protein Toxic to the Living Cells? Biochemical and Biophysical Research Communication, 1999. pp. 712-717, vol. 260.
Lubeck, et al., Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus, Proc. Natl. Acad. Sci. USA, 1989, pp. 6763-6767, vol. 86, No. 17.
Mack, et al.; Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype; Human Gene Therapy, 1997, pp. 99.109, vol. 8, No. 1.
Mastrangeli, et al., Sero-Switch Adenovirus—Mediated in Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype; Human Gene Therapy, 1996, pp. 79-87, vol. 7, No, 1.
Moffatt, et al.; Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non Human Adenoviruses: Implications in Gene Therapy, Virology, Jun. 30, 2000, pp. 159-167, vol. 272, No. 1.
Natuk, et al.; Adenovirus Vectored Vaccines, Developments in Biological Standardization , 1994, pp. 71-77, vol. 82.
Natuk, et al.; Adenovirus-human deficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model, Proc. Natl. Acad. Sci. USA, Aug. 1992, pp. 7777-7781, vol. 89, No. 16.
Natuk, et al.; Immunogenicity of Recombinant Human Adenovirus—Human Immunodeficiency Virus Vaccines in Chimpanzees, AIDS Research and Human Retroviruses, 1993, pp. 395-404, vol. 9, No. 5.
Nishimura, et al., Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies, Journal of Virology, Mar. 2002, pp. 2123-2130. vol. 76, No. 5.
Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
Parks, et al.; Use of a helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration; Gene Therapy, Sep. 1999, pp. 1565-1573, vol. 6, No. 1.
PCT International Preliminary Examination Report, PCT/EP03/50748, dated Feb. 14, 2005.
Reynolds, et al.; A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo; Molecular Therapy, 2(6); pp. 562-578. 2000.
Rodrigues, et al.; Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria, J. Immunol., Feb. 1, 1997; pp. 1268-1274, vol. 158, No. 3.
Rosenfeld, et al.; Adenovirus-Mediated Transfer of a recombinant alpha-1-Antitrypsin Gene to the Lung Epithelium in Vivo; Science, Apr. 19, 1991; pp. 431-434, vol. 252.
Roy, et al.; Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon, Journal of Virology, Aug. 1998, pp. 6875-6879, vol. 72, No. 8.
Schroter, et al.; Quantitative Detection of Hepatitis C Virus RNA by Light Cycler PCR and Comparison with Two Different PCR Assays, Journal of Clinical Microbiology, Feb. 2001, pp. 765-768, vol. 39. No. 2.
Shiver, et al. ; Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity, Nature, 2002. pp. 331-335. vol. 415, No. 6869.
Spenlehauer, et al.; A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assays That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type I, Virology. 2001, pp. 292-300, vol. 280.
Sprangers,et al.; Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors, Journal of Clinical Microbiology, Nov. 2003, pp. 5046-5052, vol. 41, No. 11.
Stallwood, et al.; Neutralisation of adenovirus infectivity by ascetic fluid from ovarian cancer patients: Gene Ther. Apr. 2000; 7(8): pp. 637-643.
Stevenson. et al.; Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain: Journal of Virology. May 1995, pp. 2850-2857, vol. 69, No. 5.
Stratford-Perricaudet. et al., Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector. Human Gene Therapy, 1990, pp. 241-256, vol. 1.
Sullivan, et al.; Development of a preventive vaccine for Ebola virus infection in primates, Nature, 2000, pp. 605-609, vol. 408, No. 6812.
Taghizadeh, et al., CRF and YFP, but Not GFP, Provide Stable Fluorescent Marking of Rat Hepatic Adult Stem Cells, Journal of Biomedicine and Biotechnology, 2008, pp. 1-9, vol. 2008, Hindawi Publishing Corporation.
Tetteh, et al.; Progress and challenges towards the development of malaria vaccines, Biogruds, 2007, pp. 357-373, vol. 21, No. 6.
Vogels, et al.; Replication-Deficient
Havenga Menzo J. E.
Kostense Stefan
Crucell Holland B.V.
Peng Bo
TraskBritt
LandOfFree
Settings for recombinant adenoviral-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Settings for recombinant adenoviral-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Settings for recombinant adenoviral-based vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2695596